Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0JT9C)

• Drug Name: DN1508052 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DM0JT9C

Molecule-Related Drug Atlas

Drug(s) Targeting Toll-like receptor 8 (TLR8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Resiquimod	DML6XSP	Actinic keratosis	EK90.0	Phase 2	[3]
Selgantolimod	DMST4OR	Hepatitis B	1E51	Phase 2	[4]
Afimetoran	DM3HN3U	Systemic lupus erythematosus	4A40.0	Phase 2	[5]
NKTR-262	DMYR8LF	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[6]
CPG 52364	DMVDYTG	Systemic lupus erythematosus	4A40.0	Phase 1	[7]
CV8102	DMYD37G	Melanoma	2C30	Phase 1	[8]
MEDI9197	DM0J7UR	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
SBT6050	DMHBD3T	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
VTX-1463	DM4ZIRK	Allergic rhinitis	CA08.0	Phase 1	[11]
GSK5251738	DM8Y6DR	Hepatitis B	1E51	Phase 1	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Toll-like receptor 8 (TLR8)	TT8CWFK	TLR8_HUMAN	Agonist	[2]

References

• [1] ClinicalTrials.gov (NCT03934359) A Study to Evaluate the Safety, Tolerability of DN1508052-01 in Advanced Solid Tumors. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Shanghai De Novo Pharmatech.
• [3] TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).Vaccine.2005 Nov 1;23(45):5263-70.
• [4] Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B. J Med Chem. 2020 Sep 24;63(18):10188-10203.
• [5] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [6] Clinical pipeline report, company report or official report of Nektar Therapeutics.
• [7] Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus. Lupus Foundation of America, Inc. 2007.
• [8] Clinical pipeline report, company report or official report of CureVac.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Clinical pipeline report, company report or official report of Silverback Therapeutics.
• [11] VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis. Expert Opin Investig Drugs. 2011 Jul;20(7):981-6.
• [12] Clinical pipeline report, company report or official report of GlaxoSmithKline